Morgan Stanley Elevates Price Target for Alnylam Pharmaceuticals (ALNY)
Money

Morgan Stanley Elevates Price Target for Alnylam Pharmaceuticals (ALNY)

authorBy Scott Pape
DateJul 14, 2026
Read Time2 min

Alnylam Pharmaceuticals, a key player in the biotechnology sector, recently saw its stock valuation revised upwards by several financial institutions. This series of adjustments reflects the dynamic nature of the pharmaceutical market and the competitive landscape of RNA interference therapeutics. Analysts are closely watching the company's trajectory, especially in light of recent clinical trial outcomes and long-term revenue projections, indicating a complex yet potentially promising future for its innovative drug pipeline.

Morgan Stanley Adjusts Price Target for Alnylam Amidst Evolving Market Dynamics

In a significant development for Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a leader in RNA interference therapeutics, Morgan Stanley raised its price target to $400 from an earlier $370 on July 10, 2026. Despite this upward revision, the firm maintained an 'Equal Weight' rating on the shares, suggesting a balanced outlook on the stock's future performance.

This adjustment from Morgan Stanley closely followed a similar move by Raymond James on July 9, where analysts increased their price target for Alnylam to $468 from $420, reiterating an 'Outperform' rating. Raymond James highlighted a crucial factor influencing their decision: Ionis' (IONS) recent unsuccessful Phase 3 ATTR-CM trial. This setback for a key competitor is perceived to significantly strengthen Alnylam's competitive standing, particularly within its TTR silencer franchise, and is expected to enhance pricing prospects for its products.

However, Raymond James also noted a potential risk associated with these developments, suggesting that the positive impact on Alnylam's current offerings might introduce some complexities for its next-generation nucresiran trial, especially concerning patients already receiving tafamidis.

Adding another perspective to the analysis, H.C. Wainwright, on June 29, lowered its price target for Alnylam to $470 from $510. Despite this reduction, the firm upheld a 'Buy' rating. Their analysis included a slight decrease in near-term estimates for Amvuttra but maintained a robust long-term forecast, predicting Alnylam's TTR franchise to generate over $20 billion in annual revenues by 2040.

Alnylam Pharmaceuticals, headquartered in the United States, is actively involved in the discovery, development, manufacturing, and commercialization of RNA interference-based therapeutics, with operations spanning across Europe and other international markets.

The collective actions of these prominent financial institutions underscore a nuanced view of Alnylam's market potential. While competitive dynamics and long-term revenue growth are positive indicators, the industry's inherent risks, particularly those related to clinical trials and evolving treatment landscapes, necessitate careful consideration for investors. The future trajectory of Alnylam will undoubtedly be shaped by its ability to navigate these challenges and capitalize on its innovative drug platforms.

More Articles
Money
Cellebrite CEO's Share Sale: Routine Transaction or Red Flag for Investors?
Cellebrite CEO Thomas Hogan recently sold 103,000 shares for $1.6 million. This article investigates whether this transaction should be a concern for investors, detailing the reasons behind the sale, Hogan's remaining stake, and the company's current financial health and market position.
By JL CollinsJul 14, 2026
Money
Freedom Capital Elevates IREN Limited to 'Buy' Rating
Freedom Capital has upgraded IREN Limited's stock to a 'Buy' rating from 'Hold', citing the company's significant upside potential following a recent dip in share prices. The firm projects an explosion in IREN's revenue, driven by its strategic expansion in data center supply. Additionally, IREN has announced key executive appointments to bolster its product strategy and global data center development, further reinforcing its position in the market.
By Vicki RobinJul 14, 2026
Money
Jefferies Maintains Positive Outlook on Pan American Silver (PAAS) Despite Price Target Adjustment
Jefferies has reiterated its 'Buy' rating for Pan American Silver (PAAS), even as it slightly reduced the price target from $54 to $53. This decision comes amidst a decline in gold prices and rising diesel costs, which are expected to impact Q2 margins. BofA also adjusted its price target for PAAS, lowering it from $77 to $69, citing revised commodity price forecasts. Despite these adjustments, both firms maintain a positive long-term view on the silver mining company.
By Vicki RobinJul 14, 2026
Money
KeyBanc Upholds 'Overweight' Rating for QXO Amidst Strategic Acquisition and Market Fluctuations
KeyBanc has reiterated its 'Overweight' rating on QXO, Inc., despite lowering the price target from $32 to $28. This adjustment follows the company's acquisition of TopBuild and prevailing market conditions. QXO's strategic move to acquire TopBuild is expected to significantly enhance its market presence and capabilities, particularly in the building products sector, with an anticipated $300 million in annual synergies by 2030. The firm remains optimistic about QXO's recovery as demand stabilizes and technological benefits become more evident.
By Vicki RobinJul 14, 2026
Money
Global Central Banks Diversify Reserves: Shifting from U.S. Dollar to Gold and Alternative Assets
A new survey reveals that central banks globally are increasingly looking to reduce their reliance on the U.S. dollar, with more institutions planning to decrease dollar exposure over the next decade. Simultaneously, gold remains a highly favored reserve asset, indicating a broader strategy of diversification to mitigate risks associated with geopolitical tensions, government debt, and evolving global trade dynamics. This trend highlights a fundamental shift in how central banks manage their reserves, prompting questions about individual investment strategies.
By Scott PapeJul 14, 2026